Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 26, 2015 3:49 PM ET

Healthcare Equipment and Supplies

Company Overview of nContact, Inc.

Company Overview

nContact, Inc. is an ablation company that engages in the development of arrhythmia and cardiovascular disease management programs for cardiac arrhythmias. The company offers ablation system devices to ensure consistent and predictable contact with cardiac tissue during the creation of linear lesions. Its solutions include EPi-Sense devices with embedded electrodes that allow for sensing and navigation of the epicardium; EPi-Sense Guided Coagulation Device with VisiTrax that integrates suction, perfusion, and RF energy to ensure cardiac tissue contact and energy transmission to create linear lesions on a beating heart; The Cannula that allows surgeons direct visualization while ablating on t...

1001 Aviation Parkway

Suite 400

Morrisville, NC 27560

United States

Founded in 2004





Key Executives for nContact, Inc.

Chief Executive Officer
Age: 54
Co-Founder and Vice President of Research & Clinicals
Co-Founder and Vice President of Development & Operations
Vice President of Finance
Compensation as of Fiscal Year 2015.

nContact, Inc. Key Developments

AtriCure, Inc., nContact, Inc. - M&A Call

To discuss AtriCure definitive agreement to acquire nContact

nContact Appoints William Hawkins as Chairman of its Board of Directors

nContact announced that William (Bill) Hawkins has been appointed as Chairman of its Board of Directors. Bill Hawkins has served as a special advisor to the nContact Board since 2013 and is a veteran entrepreneur and executive in the medical device arena, with more than 20 years of C-Suite experience in cardiology, surgery, and vascular therapies. Most recently, Bill was President and CEO of Immucor.

nContact Secures $20 Million in Growth Capital Financing

nContact announced that it has entered into a $20 million growth capital financing agreement with Hercules Technology Growth Capital, Inc. The company plans to use this financing to support its ongoing CONVERGE IDE Clinical Trial, expand its field support teams, and further next-generation product development. The randomized CONVERGE IDE clinical trial is the first head-to-head study comparing the multidisciplinary Convergent Procedure to traditional catheter ablation in the treatment of persistent AF. AF is the most common arrhythmia, affecting 15 million people in the western world, with an estimated 88% falling into the difficult-to-treat persistent AF population. The CONVERGE clinical trial randomizes patients 2:1 between the epicardial-endocardial Convergent Procedure and endocardial-only ablation with fluid-irrigated catheters.

Similar Private Companies By Industry

Company Name Region
Custom Spine, Inc. United States
NDI Medical, Inc. United States
Clinical Innovations, LLC United States
Whitmyer Biomechanix, Inc. United States
SpineVision, Inc. United States

Recent Private Companies Transactions

October 4, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact nContact, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at